Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

BACKGROUND AND OBJECTIVE: Ciltacabtagene autoleucel (cilta-cel) is a novel agent being investigated in the single-arm CARTITUDE-1 trial (NCT03548207) for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Katja, Martin, Thomas, Krishnan, Amrita, Jagannath, Sundar, Londhe, Anil, Nair, Sandhya, Diels, Joris, Vogel, Martin, Schecter, Jordan M., Banerjee, Arnob, Berdeja, Jesus G., Nesheiwat, Tonia, Garrett, Ashraf, Qi, Keqin, Valluri, Satish, Usmani, Saad Z., Yong, Kwee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755696/
https://www.ncbi.nlm.nih.gov/pubmed/34822128
http://dx.doi.org/10.1007/s40261-021-01100-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755696/
https://www.ncbi.nlm.nih.gov/pubmed/34822128
http://dx.doi.org/10.1007/s40261-021-01100-y

Ejemplares similares